SearcharxivSearch

arXiv subjects

Sarah L. Kerns

Publications and source records attributed to Sarah L. Kerns.

2 recordsLinked to original sources

Data-adaptive gene and pathway-based tests forrare-variant associations with survival outcomes

Statistical methods for testing aggregate rare-variant genetic associations are typically based on either burden or dispersion tests (or a combination of the two). These methods lack statistical power in the presence of diverse genetic architectures. Moreover, few aggregate rare-variant association methods have been developed specifically for survival data. To address these issues, we propose data-adaptive gene- and pathway-based association tests based on Schoenfeld residuals in Cox proportional hazards models for association studies between an aggregate of rare-variants and survival outcomes. Our methods improve statistical power while maintaining flexibility across various genetic effect sizes and directions. We develop an efficient R package that enables fast computation and supports data simulation as well as gene- and pathway-level testing. Applying our approach to late bladder toxicity following radiotherapy for non-metastatic prostate cancer, we identify biologically relevant genes and pathways, replicate known signals, and capture additional associations. Our method provides a powerful, adaptive framework for survival-based genetic association studies of rare-variants. Keywords: aSPU, time-to-event outcomes, rare-variant associations, Cox regression, Schoenfeld residuals

stat.ME

Genomics models in radiotherapy: from mechanistic to machine learning

Machine learning provides a broad framework for addressing high-dimensional prediction problems in classification and regression. While machine learning is often applied for imaging problems in medical physics, there are many efforts to apply these principles to biological data towards questions of radiation biology. Here, we provide a review of radiogenomics modeling frameworks and efforts towards genomically-guided radiotherapy. We first discuss medical oncology efforts to develop precision biomarkers. We next discuss similar efforts to create clinical assays for normal tissue or tumor radiosensitivity. We then discuss modeling frameworks for radiosensitivity and the evolution of machine learning to create predictive models for radiogenomics.

stat.AP